Ensysce Biosciences, Inc. operates as a biotechnology company that develops abuse-resistant drug technologies. It offers TAAP, a trypsin-activated abuse protection technology that prevents abuse through a two-step internal trypsin-activation process to meet the medical needs of patients living with chronic pain; and MPAR, a multi-pill abuse resistant technology that provides a layer of protection for overdose. The company was incorporated in 2003 and is based in La Jolla, California.
Research context
Leisure Acquisition Corp appears in PyInvesting’s US Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- USD
- Sector
- Financial Services
- Industry
- Shell Companies
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
5 years, 7 months ago
Leisure Acquisition Corp is currently in a long term uptrend where the price is trading 12.1% above its 200 day moving average.
From a valuation standpoint, the stock is 100.0% cheaper than other stocks from the Financial Services sector with a price to sales ratio of 0.0.
Leisure Acquisition Corp's total revenue sank by nan% to $0 since the same quarter in the previous year.
Its net income has increased by 94.3% to $-75K since the same quarter in the previous year.
Finally, its free cash flow grew by 7.1% to $-396K since the same quarter in the previous year.
Based on the above factors, Leisure Acquisition Corp gets an overall score of 4/5.